ClinicalTrials.gg

Program

HDM1002

A development code. Also written as “HDM1002 200 mg”, “HDM1002 400 mg” and “HDM1002 100 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Overweight · Obesity, led by Huadong Medicine.

Furthest: phase 3, since Mar 13, 202513 company-led studies, 11 open or runningNext primary completion: Feb 16, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Huadong Medicine1311 open or runningphase 3since Mar 13, 2025Jun 13, 2024Feb 16, 2027phase 3 · NCT07082114

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 13, 2024First studies: 2 phase 2 studiesFirst studyNCT06500299, NCT06481085
  2. Jul 9, 2024Phase 1 study in Glucagon-Like Peptide-1 Receptor AgonistsNCT06520540 · 72 planned · China
  3. Aug 13, 20242 phase 1 studies in Healthy Adult SubjectNCT06562088, NCT06576401
  4. Sep 3, 20242 phase 1 studies in Healthy Adult SubjectNCT06601517, NCT06608329
  5. Mar 13, 2025Phase 3 study in OverweightNCT06885021 · 780 planned
  6. May 15, 2025Phase 1 study in Hepatic ImpairmentNCT06985615 · 40 planned · China
  7. Jul 10, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07082114 · 800 planned · China
  8. Sep 1, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07193459 · 360 planned · China
  9. Nov 18, 2025Phase 1 study in Overweight SubjectNCT07331389 · 111 planned · China
  10. May 6, 2026Phase 1 study in Healthy Adult SubjectNCT07594847 · 72 planned · China

Ahead

  1. Feb 16, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07082114

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07594847Healthy Adult Subject · China1RecruitingSep 25, 202672
NCT07331389Overweight Subject · China1RecruitingJan 12, 2026111
NCT07193459Diabetes Mellitus, Type 2 · China3RecruitingOct 10, 2026360
NCT07082114Diabetes Mellitus, Type 2 · China3RecruitingFeb 16, 2027800
NCT06985615Hepatic Impairment · China1RecruitingJan 14, 202640
NCT06885021Overweight3Not yet recruitingMay 30, 2026780
NCT06608329Healthy Adult Subject · China1Not yet recruitingNov 202433
NCT06601517Healthy Adult Subject · China1Not yet recruitingFeb 202530
NCT06576401Healthy Adult Subject · China1RecruitingOct 202410
NCT06562088Healthy Adult Subject · China1UNKNOWNNov 19, 202440
NCT06520540Glucagon-Like Peptide-1 Receptor Agonists · China1Not yet recruitingNov 30, 202472
NCT06500299Overweight2Not yet recruitingOct 30, 2024180
NCT06481085Diabetes Mellitus, Type 2 · China2CompletedMay 30, 2025324

How it is read

Names in the registry

  • “HDM1002 200 mg”, 4 entries
  • “HDM1002 400 mg”, 4 entries
  • “HDM1002”, 3 entries
  • “HDM1002 100 mg”, 2 entries
  • “HDM1002 200 mg QD 12weeks”, 2 entries

Codes read as this program: HDM1002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
HDM1002 (Huadong Medicine): development program | ClinicalTrials.gg